JP Morgan Maintains Underweight on Agilon Health, Raises Price Target to $85
JP Morgan analyst Lisa Gill maintains Agilon Health (NYSE:AGL) with a Underweight and raises the price target from $31 to $85.
Stocks · News reference
CORRECTION: Agilon Health Raises FY2026 Sales Guidance from $5.680B-$5.805B to $5.775B-$5.860B vs $5.719B Est
Agilon Health (NYSE:AGL) raises FY2026 sales outlook from $5.680 billion-$5.805 billion to $5.775 billion-$5.860 billion vs $5.719 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $146
Wells Fargo analyst Stephen Baxter maintains Agilon Health (NYSE:AGL) with a Overweight and raises the price target from $141 to $146.
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts upgraded various stocks, including BBY, BCE. See what other analysts think.
Citigroup Upgrades Agilon Health to Neutral, Raises Price Target to $115
Citigroup analyst Daniel Grosslight upgrades Agilon Health (NYSE:AGL) from Sell to Neutral and raises the price target from $105 to $115.